Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastomaJasmine Y. Lee(Emory University), Kelly C. Goldsmith(Emory University)Cell Reports MedicineJune 1, 202310.1016/j.xcrm.2023.101091Cited by 16SaveCiteExport RISWatch citationsRelated PapersLorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results|Nature Medicine|2023|125Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma|Clinical Cancer Research|2018|88Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma|BMC Cancer|2016|38